NVAX Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Vaccine Technology PlatformNovavax is built around a defined protein-based vaccine platform rather than a single product alone. Its recombinant nanoparticle technology and Matrix-M adjuvant provide a reusable foundation for developing additional infectious-disease vaccines over the medium term.
Partnership-Based Commercial ModelCollaboration and licensing arrangements can broaden Novavax’s manufacturing reach and commercial access without requiring the company to perform every activity internally. This model may support multiple revenue streams and improve scalability across vaccine programs.
Demonstrated Profit PotentialNovavax has demonstrated that its business can produce substantial revenue and profitability under favorable commercial conditions. That history supports the potential for operating leverage if vaccine demand, authorizations, and procurement activity again align constructively.
Bears Say
Revenue And Profitability DeteriorationThe recent reversal from strong 2025 results to lower trailing revenue and renewed losses shows that earnings are highly dependent on changing vaccine demand and procurement timing. This volatility makes near-term financial performance less predictable.
Persistent Negative EquityA continuing equity deficit weakens the balance sheet and limits financial flexibility during periods of weaker operating performance. It also leaves the company more reliant on liabilities or external capital to support operations and pursue future growth.
Ongoing Cash BurnSustained negative operating and free cash flow means the business is not currently funding itself through ongoing operations. Continued cash burn can constrain investment in vaccine development and increase dependence on external funding over the next several quarters.
Novavax News
NVAX FAQ
What was Novavax’s price range in the past 12 months?
Currently, no data Available
What is Novavax’s market cap?
Novavax’s market cap is CHF1.74B.
When is Novavax’s upcoming earnings report date?
Novavax’s upcoming earnings report date is Nov 05, 2026 which is in 22 days.
How were Novavax’s earnings last quarter?
Novavax released its earnings results on Aug 06, 2026. The company reported -CHF0.266 earnings per share for the quarter, beating the consensus estimate of -CHF0.316 by CHF0.05.
Is Novavax overvalued?
According to Wall Street analysts Novavax’s price is currently Undervalued.
Does Novavax pay dividends?
Novavax does not currently pay dividends.
What is Novavax’s EPS estimate?
Novavax’s EPS estimate is -0.18.
How many shares outstanding does Novavax have?
Currently, no data Available
What happened to Novavax’s price movement after its last earnings report?
Novavax reported an EPS of -CHF0.266 in its last earnings report, beating expectations of -CHF0.316. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Novavax?
Currently, no hedge funds are holding shares in CH:NVAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novavax Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
CHF9.72 (― Downside)
CHF9.72 (― Downside)
Blogger Sentiment
Bullish
CH:NVAX Sentiment 92%
Sector Average 67%
Sector Average 67%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
48.72%
12-Months-Change
Fundamentals
Return on Equity
159.85%
Trailing 12-Months
Asset Growth
-28.50%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Novavax
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
NVAX Company Deck
NVAX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong strategic progress: rapid expansion of partner collaborations, material partner-driven revenue growth, improved cash position and meaningful reductions in operating costs. Management showcased encouraging preclinical data (notably for a prioritized C. difficile asset) and reiterated 2026 guidance while outlining a credible path to non-GAAP profitability by 2028. Near-term challenges include a large YoY revenue decline driven by a prior-period noncash item, modest direct product sales, continued reliance on partners to convert MTAs to licensed programs and some near-term expense support for partners. On balance, the highlights—particularly partnership momentum, partner-revenue growth, cash runway and cost reductions—substantially outweigh the lowlights, though execution and timing risks remain.View all CH:NVAX earnings summariesNVAX Stock 12 Month Forecast
Average Price Target
CHF9.72
Vir Biotechnology
―
Oric Pharmaceuticals
―
―
AbCellera Biologics
―
Sana Biotechnology
―